Close Menu

NEW YORK (GenomeWeb) – Becton Dickinson said today that its BD Max MDR-TB panel has received CE-IVD status and is now available in Europe.

The PCR-based panel is intended to help detect tuberculosis-causing bacteria and determine if the bacteria contains mutations associated with resistance to isoniazid and rifampicin, two important first-line TB drugs.

The assay runs on the BD Max system, a fully integrated and automated molecular diagnostics platform that can run up to 24 samples across multiple tests and provides results for most assays in less than three hours.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.